These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38834655)

  • 1. PARP7 and nucleic acid-driven oncosuppression.
    Naulin F; Guilbaud E; Galluzzi L
    Cell Mol Immunol; 2024 Nov; 21(11):1177-1179. PubMed ID: 38834655
    [No Abstract]   [Full Text] [Related]  

  • 2. Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-β signaling.
    Sanderson DJ; Rodriguez KM; Bejan DS; Olafsen NE; Bohn ID; Kojic A; Sundalam S; Siordia IR; Duell AK; Deng N; Schultz C; Grant DM; Matthews J; Cohen MS
    Cell Chem Biol; 2023 Jan; 30(1):43-54.e8. PubMed ID: 36529140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.
    Gozgit JM; Vasbinder MM; Abo RP; Kunii K; Kuplast-Barr KG; Gui B; Lu AZ; Molina JR; Minissale E; Swinger KK; Wigle TJ; Blackwell DJ; Majer CR; Ren Y; Niepel M; Varsamis ZA; Nayak SP; Bamberg E; Mo JR; Church WD; Mady ASA; Song J; Utley L; Rao PE; Mitchison TJ; Kuntz KW; Richon VM; Keilhack H
    Cancer Cell; 2021 Sep; 39(9):1214-1226.e10. PubMed ID: 34375612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors.
    Zhang S; Zhang Y; Wang Z; Qing L; Fu S; Xu J; Li Y; Fang H; He H
    Eur J Med Chem; 2023 Dec; 261():115836. PubMed ID: 37826932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP7-mediated ADP-ribosylation of FRA1 promotes cancer cell growth by repressing IRF1- and IRF3-dependent apoptosis.
    Manetsch P; Böhi F; Nowak K; Leslie Pedrioli DM; Hottiger MO
    Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2309047120. PubMed ID: 38011562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of PARP7 Protein Levels and PARP7 Inhibitor Target Engagement in Cells Using a Split Nanoluciferase System.
    Duell AK; Sanderson DJ; Cohen MS
    Methods Mol Biol; 2023; 2609():387-395. PubMed ID: 36515849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of PARP7 Increases Type I Interferon Signaling in EO771 Breast Cancer Cells and Prevents Mammary Tumor Growth by Increasing Antitumor Immunity.
    Rasmussen M; Alvik K; Kannen V; Olafsen NE; Erlingsson LAM; Grimaldi G; Takaoka A; Grant DM; Matthews J
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells.
    Yang C; Wierbiłowicz K; Dworak NM; Bae SY; Tengse SB; Abianeh N; Drake JM; Abbas T; Ratan A; Wotton D; Paschal BM
    Cancer Res Commun; 2023 Apr; 3(4):592-606. PubMed ID: 37077937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-Transcriptional Regulation of PARP7 Protein Stability Is Controlled by Androgen Signaling.
    Kamata T; Yang CS; Melhuish TA; Frierson HF; Wotton D; Paschal BM
    Cells; 2021 Feb; 10(2):. PubMed ID: 33572475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced Colonic Mucosal Injury in 2,3,7,8-Tetrachlorodibenzo-
    Hutin D; Hagen KA; Shao P; Sugamori K; Grant DM; Matthews J
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP7 and Mono-ADP-Ribosylation Negatively Regulate Estrogen Receptor α Signaling in Human Breast Cancer Cells.
    Rasmussen M; Tan S; Somisetty VS; Hutin D; Olafsen NE; Moen A; Anonsen JH; Grant DM; Matthews J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33799807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP7 mono-ADP-ribosylates the agonist conformation of the androgen receptor in the nucleus.
    Kamata T; Yang CS; Paschal BM
    Biochem J; 2021 Aug; 478(15):2999-3014. PubMed ID: 34264286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells.
    Spirtos AN; Aljardali MW; Challa S; Koul S; Lea JS; Kraus WL; Camacho CV
    bioRxiv; 2024 Sep; ():. PubMed ID: 39229139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors.
    Gu H; Yan W; Wang Y; Xu W; Huang L; Yang J; Zhai B; Wang H; Su Y; Zhu Q; Liu B; Hao H; Zou Y; Xu Y
    J Med Chem; 2023 Jan; 66(1):473-490. PubMed ID: 36576395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy.
    Gu H; Yan W; Yang J; Liu B; Zhao X; Wang H; Xu W; Wang C; Chen Y; Dong Q; Zhu Q; Xu Y; Zou Y
    J Med Chem; 2024 Feb; 67(3):1932-1948. PubMed ID: 38059836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP7 Inhibition: A Promising Pathway to Advancements in Cancer Therapy.
    Kargbo RB
    ACS Med Chem Lett; 2023 Sep; 14(9):1141-1143. PubMed ID: 37736186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of highly potent PARP7 inhibitors for cancer immunotherapy.
    Yang J; Liu B; Yan W; Zhao X; Wang C; Zhu Q; Zou Y; Xu Y; Gu H
    Bioorg Chem; 2024 Jul; 148():107469. PubMed ID: 38781669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability.
    Xu J; Zhao A; Chen D; Wang J; Ma J; Qing L; Li Y; Fang H; He H; Pan W; Zhang S
    Eur J Med Chem; 2024 Feb; 266():116160. PubMed ID: 38277917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP7 Inhibitors and AHR Agonists Act Synergistically Across a Wide-Range of Cancer Models.
    Chen H; Gou X; Mao Y; O'Leary PC; Diolaiti ME; Ashworth A
    Mol Cancer Ther; 2024 Sep; ():. PubMed ID: 39313957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel PARP7 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Dec; 14(12):1615-1616. PubMed ID: 38116422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.